Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Immunovant Inc (NASDAQ: IMVT) closed at $17.93 up 2.52% from its previous closing price of $17.49. In other words, the price has increased by $2.52 from its previous closing price. On the day, 1.67 million shares were traded. IMVT stock price reached its highest trading level at $18.065 during the session, while it also had its lowest trading level at $17.41.
Ratios:
For a deeper understanding of Immunovant Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.32 and its Current Ratio is at 12.32. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Truist on October 14, 2025, initiated with a Hold rating and assigned the stock a target price of $16.
On March 03, 2025, Jefferies started tracking the stock assigning a Hold rating and target price of $20.Jefferies initiated its Hold rating on March 03, 2025, with a $20 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 08 ’25 when Geffner Michael sold 1,272 shares for $16.30 per share. The transaction valued at 20,734 led to the insider holds 220,553 shares of the business.
Stout Jay S sold 1,585 shares of IMVT for $25,836 on Oct 08 ’25. The Chief Technology Officer now owns 203,334 shares after completing the transaction at $16.30 per share. On Jul 23 ’25, another insider, Stout Jay S, who serves as the Chief Technology Officer of the company, sold 2,805 shares for $18.15 each. As a result, the insider received 50,911 and left with 204,919 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMVT now has a Market Capitalization of 3125501184 and an Enterprise Value of 2526588928.
Stock Price History:
The Beta on a monthly basis for IMVT is 0.55, which has changed by -0.40225565 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, IMVT has reached a high of $32.10, while it has fallen to a 52-week low of $12.72. The 50-Day Moving Average of the stock is 13.17%, while the 200-Day Moving Average is calculated to be 2.81%.
Shares Statistics:
For the past three months, IMVT has traded an average of 1.52M shares per day and 1476400 over the past ten days. A total of 171.07M shares are outstanding, with a floating share count of 70.59M. Insiders hold about 59.50% of the company’s shares, while institutions hold 55.41% stake in the company. Shares short for IMVT as of 1759190400 were 16268540 with a Short Ratio of 10.67, compared to 1756425600 on 15570264. Therefore, it implies a Short% of Shares Outstanding of 16268540 and a Short% of Float of 27.21.
Earnings Estimates
. The current rating of Immunovant Inc (IMVT) reflects the combined expertise of 14.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.73, with high estimates of -$0.6 and low estimates of -$0.87.
Analysts are recommending an EPS of between -$2.33 and -$3.32 for the fiscal current year, implying an average EPS of -$2.89. EPS for the following year is -$3.0, with 11.0 analysts recommending between -$1.96 and -$3.98.
